Tue, May 13, 8:41 PM (41 days ago)
**Annovis Bio, Inc. (ANVS) Q1 2025 Financial Summary** **Financial Health:** - **Cash Position:** Annovis Bio reported $22.2 million in cash and cash equivalents as of March 31, 2025, up from $10.6 million at the end of 2024. - **Total Assets:** Increased to $26.7 million from $13.9 million. - **Liabilities:** Total liabilities decreased to $2.7 million from $4.6 million. - **Stockholders' Equity:** Increased to $24.1 million from $9.3 million. **Performance Metrics:** - **Revenue:** No revenue generated; the company is in the clinical development stage. - **Operating Expenses:** Decreased to $6.3 million from $7.8 million, primarily due to reduced clinical trial costs offset by increased labor and API expenses. - **Net Loss:** Increased to $5.5 million from $1.1 million, largely due to changes in the fair value of warrants. - **Profit Margins:** Not applicable as the company is not generating revenue. **Cash Flow:** - **Operating Activities:** Cash used was $8.1 million, up from $7.0 million, due to increased clinical trial expenses. - **Financing Activities:** Provided $19.8 million, primarily from the ThinkEquity offering and ATM facility. - **Net Increase in Cash:** $11.7 million, reflecting the significant financing activities. **Earnings Changes:** - **Net Loss per Share:** Basic and diluted net loss per share increased to $0.32 from $0.10 and $0.72, respectively. - **Weighted-Average Shares:** Increased to 17.4 million from 10.6 million due to equity issuances. **Quarterly Performance Discussion:** - **Research and Development:** Focused on Phase 3 AD and PD studies, with increased costs for clinical labor and API. - **General and Administrative:** Relatively stable with no significant changes. - **Interest Income:** Increased due to higher cash balances post-ThinkEquity offering. - **Change in Fair Value of Warrants:** Significant decrease due to fewer warrants outstanding and stock price changes. **Trends and Uncertainties:** - **Funding Requirements:** The company expects to need substantial additional capital to complete development and commercialization. - **Operational Risks:** Dependence on successful fundraising, regulatory approvals, and market acceptance of product candidates. - **Future Operations Impact:** Continued development of buntanetap for AD and PD, with plans for additional clinical trials and potential NDA filings. **Future Outlook:** - **Cash Runway:** Expected to fund operations until Q4 2025. - **Financing Plans:** Plans to raise additional capital through equity offerings, debt financings, or collaborations. - **Clinical Trials:** Ongoing Phase 3 AD trial and potential additional trials based on regulatory discussions. **Conclusion:** Annovis Bio is in a critical phase of clinical development, with significant financial and operational challenges ahead. The company's ability to secure additional funding and successfully complete clinical trials will be crucial for its future success.